Lytix Biopharma AS - Asset Resilience Ratio

Latest as of December 2025: 88.76%

Lytix Biopharma AS (LYTIX) has an Asset Resilience Ratio of 88.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LYTIX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Nkr72.36 Million

≈ $7.61 Million USD Cash + Short-term Investments

Total Assets

Nkr81.52 Million

≈ $8.58 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Lytix Biopharma AS's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Lytix Biopharma AS assets under control.

Liquid Assets Composition Over Time

This chart breaks down Lytix Biopharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read LYTIX total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Nkr10.60 Million	13.0%
Short-term Investments	Nkr61.76 Million	75.75%
Total Liquid Assets	Nkr72.36 Million	88.76%

Asset Resilience Insights

Very High Liquidity: Lytix Biopharma AS maintains exceptional liquid asset reserves at 88.76% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Lytix Biopharma AS Industry Peers by Asset Resilience Ratio

Compare Lytix Biopharma AS's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Lytix Biopharma AS (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Lytix Biopharma AS.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	88.76%	Nkr72.36 Million ≈ $7.61 Million	Nkr81.52 Million ≈ $8.58 Million	-0.50pp
2024-12-31	89.26%	Nkr130.79 Million ≈ $13.76 Million	Nkr146.53 Million ≈ $15.42 Million	+10.12pp
2023-12-31	79.14%	Nkr50.55 Million ≈ $5.32 Million	Nkr63.87 Million ≈ $6.72 Million	-16.35pp
2022-12-31	95.49%	Nkr145.16 Million ≈ $15.27 Million	Nkr152.02 Million ≈ $16.00 Million	-1.71pp
2021-12-31	97.20%	Nkr197.28 Million ≈ $20.76 Million	Nkr202.96 Million ≈ $21.36 Million	+9.98pp
2020-12-31	87.22%	Nkr28.45 Million ≈ $2.99 Million	Nkr32.62 Million ≈ $3.43 Million	+13.83pp
2019-12-31	73.40%	Nkr12.80 Million ≈ $1.35 Million	Nkr17.43 Million ≈ $1.83 Million	-10.85pp
2018-12-31	84.25%	Nkr49.62 Million ≈ $5.22 Million	Nkr58.90 Million ≈ $6.20 Million	+10.01pp
2017-12-31	74.23%	Nkr34.96 Million ≈ $3.68 Million	Nkr47.09 Million ≈ $4.96 Million	--

pp = percentage points

About Lytix Biopharma AS

OL:LYTIX Norway Biotechnology

Market Cap

$68.78 Million

Nkr653.65 Million NOK

Market Cap Rank

#20759 Global

#186 in Norway

Share Price

Nkr8.50

Change (1 day)

+1.43%

52-Week Range

Nkr6.90 - Nkr11.50

All Time High

Nkr18.60